智通财经APP讯，复宏汉霖(02696)发布公告，合计1.83亿股非上市股已于2026年2月4日完成转换为H 股，该等转换H股将于2026年2月5日上午九时正开始于联交所上市。 ...

复宏汉霖(02696)发布公告，合计1.83亿股非上市股已于2026年2月4日完成转换为H股，该等转换H股将 于2026年2月5日上午九时正开始于联交所上市。 ...

派林生物（000403）(000403.SZ)公告，公司全资子公司广东双林生物制药有限公司(称"广东双林")收到 国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。 ...

智通财经APP讯，派林生物(000403.SZ)公告，公司全资子公司广东双林生物制药有限公司(称"广东双 林")收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。 ...

格隆汇2月4日丨派林生物(000403.SZ)公布，全资子公司广东双林生物制药有限公司（简称"广东双林"） 收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通知书》。人凝血因子IX 适应症：对于治疗先天性人凝血因子Ⅸ缺失的乙型血友病患者或因其它原因引起的人凝血因子Ⅸ含量低 下的患者，可显著提升其血液中人凝血因子Ⅸ的水平，从而达到预防和治疗出血的目的。乙型血友病属 罕见病，长期临床用药紧缺，现有治疗用药活性回收率待提升。公司长期以患者为中心，将致力于研发 高回收率的血源性药品。 ...

派林生物公告，近日，全资子公司广东双林生物制药有限公司收到国家药品监督管理局核准签发的人凝 血因子IX药品注册上市许可《受理通知书》（受理号：XCSS2600002）。人凝血因子IX适应症：对于 治疗先天性人凝血因子Ⅸ缺失的乙型血友病患者或因其它原因引起的人凝血因子Ⅸ含量低下的患者，可 显著提升其血液中人凝血因子Ⅸ的水平，从而达到预防和治疗出血的目的。 ...

Core Viewpoint - The Sci-Tech Innovation 50 Index experienced a decline, closing at 1453.48 points with a drop of 1.20% on February 4, 2023, amidst a total trading volume of approximately 765.9 billion yuan [1]. Group 1: Market Performance - The majority of stocks on the Sci-Tech Board saw declines, with 209 stocks rising. High-priced stocks showed mixed performance while low-priced stocks mostly increased [2]. - On average, the 600 stocks on the Sci-Tech Board experienced a decline of 0.64%, with an average turnover rate of 2.89% and a total trading volume of 242.9 billion yuan, alongside an average fluctuation of 4.16% [2]. Group 2: Individual Stock Performance - Shichuang Energy and JinkoSolar led the gainers with a rise of 20%, while Kaipu Cloud had the largest drop at 12.57% [3]. - In terms of trading volume, Cambrian Technology topped the list with a trading volume of 12.6 billion yuan, while Hanbang Technology had the lowest at 1.302 million yuan [4]. Group 3: Turnover Rate - Hengyun Chang had the highest turnover rate at 26.8%, while Bairen Medical recorded the lowest turnover rate at 0.17% [5].

Group 1 - The core point of the article is that Zhifei Biological's subsidiary has received approval for clinical trials of a new vaccine aimed at preventing chickenpox and shingles [1] Group 2 - Zhifei Longkema, a wholly-owned subsidiary of Zhifei Biological, is responsible for the development of the lyophilized inactivated chickenpox vaccine [1] - The approval was granted by the National Medical Products Administration, allowing the company to proceed with clinical trials [1]

Core Viewpoint - The company Zhifei Biological Products Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its lyophilized varicella inactivated vaccine, aimed at preventing chickenpox caused by varicella-zoster virus infection [1] Group 1 - The clinical trial approval is granted to the company's wholly-owned subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. [1] - The vaccine is intended to address infections caused by the varicella-zoster virus, which leads to chickenpox [1]

Core Viewpoint - Changchun High-tech has reported its worst performance in nearly two decades, with a projected net profit of 150 million to 220 million yuan for 2025, representing a year-on-year decline of 91.48% to 94.19% [2] Financial Performance - The company experienced a significant decline in net profit for the first three quarters of 2025, amounting to 1.165 billion yuan, a decrease of 58.23% year-on-year [2] - The fourth quarter is expected to incur a massive loss of 945 million to 1.015 billion yuan, with a year-on-year increase in losses of 358.74% to 392.72% [2] Business Dependency - The core issue behind the performance decline is the company's heavy reliance on its growth hormone business, which has historically contributed nearly 100% of its net profit [2] - The net profits of Jinsai Pharmaceutical, a subsidiary responsible for the growth hormone business, were 4.217 billion yuan and 4.514 billion yuan in 2022 and 2023, respectively, closely aligning with the overall net profit of Changchun High-tech during the same periods [2] Market Changes - The long-acting growth hormone Jinsai was included in the national medical insurance directory, with a significant price reduction of approximately 75% for the 9mg specification [3] - The inclusion in the medical insurance directory has ended the high-profit era for this business, leading to a drastic compression of profit margins [3] - The market landscape for growth hormones has fundamentally changed, with competitors like Teva Biopharma and Novo Nordisk entering the market, further intensifying price competition [3] R&D and Sales Strategy - To reduce dependency on a single product, the company has increased R&D investment, reaching 2.69 billion yuan in 2024, accounting for 20.0% of revenue [4] - In the first three quarters of 2025, R&D investment was 1.733 billion yuan, a year-on-year increase of 22.96%, representing 17.68% of revenue [4] - Sales expenses have also risen significantly, reaching 3.764 billion yuan in the first three quarters of 2025, accounting for 38.38% of revenue, up from 32.96% in 2024 [4] Transition Challenges - The company is currently facing a transitional phase characterized by the loss of its "old engine" (growth hormone business) and the underperformance of new products [4] - Short-term risks include uncertainties in innovative drug development and underwhelming commercialization of new products, which may prolong the period of performance stabilization [4] - However, in the long term, the short-term impact of price reductions from medical insurance is expected to be absorbed, with the growth hormone business potentially maintaining stable cash flow as prices stabilize and market penetration increases [4]